In addition, Chitosan has been shown to improve glycolipid metabolic disorders by inhibiting inflammation and up-regulating peroxisome proliferator-activated receptor gamma expression, including by inducing weight loss, reducing fasting blood glucose levels, restoring intraperitoneal glucose tolerance, inhibiting overexpression of pro-inflammatory cytokines, and regulating factors related to glycolipid metabolism [62, 63]. This evidence concerns the gene PPARG and metabolic disease.